Treating Cystic Fibrosis: An Evaluation Of Aeroquin®, A New Aerosolized Form Of Levofloxacin

SynteractHCR is a privately held contract research organization (CRO) dedicated to meeting the needs of biotech, pharmaceutical and medical device companies. SynteractHCR provides high quality, full-service clinical research services to support its client’s global drug and device development projects, and prides itself on working collaboratively as an extension of the client’s team.

The study was designed to evaluate the efficacy, safety and tolerability of Aeroquin®, a new aerosolized form of Levofloxacin, to treat CF. Aeroquin was administered in three dosage regimens over 28 days compared to a placebo drug. The trials were conducted in the U.S., Germany and the Netherlands, to assess Aeroquin’s effectiveness against P. aeruginosa (bacteria in the lungs that causes infection), as well as against other organisms that colonize the lungs of CF patients.